L. Martelo-Vidal
6 Papers
1 Citations
L. Martelo-Vidal is an academic researcher. The author has contributed to research in topics: Immunology & Medicine. The author has an hindex of 1, co-authored 4 publications.
Chat about Author
Papers
Serum exosome inflamma‐miRs are surrogate biomarkers for asthma phenotype and severity
S. Vázquez-Mera,L. Martelo-Vidal,P. Miguéns-Suárez,Paula Saavedra-Nieves,Pilar Arias,Coral González-Fernández,Mar Mosteiro-Añón,María Dolores Corbacho-Abelaira,Marina Blanco-Aparicio,P Méndez-Brea,Francisco J. Salgado,Juan-José Nieto-Fontarigo,Francisco-Javier González-Barcala +12 more
TL;DR: Immune-related miRNAs, includingmiR-21-5p, miR-126-3p,MiR-146a- 5p, and miR -215-5P can be used as clinically relevant non-invasive biomarkers of the phenotype/endotype and severity of asthma.
41
Mepolizumab alters the phenotype and activation status of peripheral blood eosinophils in patients with severe eosinophilic asthma
P. Miguéns-Suárez,S. Vázquez-Mera,L. Martelo-Vidal,Uxio Calvo-Alvarez,Raquel Ruiz-Ferreras,Marina Blanco-Aparicio,Coral González-Fernández,Mar Mosteiro-Añón,María Dolores Corbacho-Abelaira,P Méndez-Brea,Juan-José Nieto-Fontarigo,Francisco-Javier Salgado,Francisco-Javier González-Barcala +12 more
- 09 Sep 2023
TL;DR: Mepolizumab treatment in severe eosinophilic asthma patients decreases peripheral blood eosinophil number and activation status, inducing a transition from inflammatory to resident eosinophils, and restores eosinophil function to healthy control levels.
2
Application of urinary proteomics for biomarker discovery in respiratory diseases
L. Martelo-Vidal,S. Vázquez-Mera,P. Miguéns-Suárez,Francisco-Javier Salgado-Castro,Marina Blanco-Aparicio,Mar Mosteiro-Añón,Gabriel Martínez-Capoccioni,P Méndez-Brea,Susana B. Bravo,Francisco-Javier González-Barcala,Juan-José Nieto-Fontarigo +10 more
- 04 Sep 2022
TL;DR: In this article , the authors used non-targeted proteomics in urine with applicability to different pulmonary diseases to search for molecular biomarkers of pulmonary pathologies using non-invasive samples, such as urine, is of high clinical relevance.
1
Exosomal miR16, miR21, miR126, miR146a and miR215 as biomarkers for asthma severity
S. Vázquez Mera,P. Miguéns-Suárez,L. Martelo-Vidal,Uxio Calvo-Alvarez,Javier Rodríguez-García,Coral González-Ferández,Mar Mosteiro-Añón,Marina Blanco-Aparicio,Juan-José Nieto-Fontarigo,Francisco-Javier Salgado-Castro,Francisco-Javier González-Barcala +10 more
- 10 Mar 2022
TL;DR: In this paper , the levels (RTqPCR) of 12 miRNAs in serum exosomes from healthy controls and asthma patients (n=30) were compared to mild-intermittent asthmatics.
1
Mepolizumab treatment alters the functional phenotype of eosinophils in severe eosinophilic asthma
P. Miguéns-Suárez,L. Martelo-Vidal,S. Vázquez-Mera,Marina Blanco-Aparicio,Uxio Calvo-Alvarez,Coral González-Fernández,Mar Mosteiro-Añón,Dolores Corbacho-Abelaira,T. Hermida-Valverde,C. Calvo-Henríquez,Juan-José Nieto-Fontarigo,Francisco-Javier Salgado,Francisco-Javier González-Barcala +12 more
TL;DR: Mepolizumab treatment in severe eosinophilic asthma alters the functional phenotype of eosinophils, reducing inflammatory eosinophils and activation status, with changes evident as early as 4 weeks and sustained through 32 weeks of treatment.